Association between biologic exposure and relapse incidence in relapsing polychondritis: a retrospective cohort study

Clicks: 1
ID: 317147
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #148 of 202 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
OBJECTIVES: Relapsing polychondritis (RP) is characterised by recurrent flares, and comparative evidence for relapse prevention using biologics remains limited. We evaluated the association between biologic exposure and relapse incidence. METHODS: This single-centre retrospective cohort study (Kyoto University Hospital, 2000-2023) investigated adults with RP. Follow-up was divided into periods without biologics (No Bio), with TNF-α inhibitors (TNFi), or with IL-6 receptor inhibitor (IL-6Ri). Primary outcomes were RP relapse and hospitalised infection. Period-level incidence rate ratios were estimated using negative binomial regression with a log(person-time) offset and adjusted for prespecified covariates, and adjusted absolute event rates and rate differences were estimated by regression standardisation. RESULTS: Over 503.5 person-years, 55 patients were included (never-Bio, n = 28; ever-Bio, n = 27). Within the ever-Bio cohort, crude relapse rates were 46.9, 22.4, and 12.5 per 100 person-years during the No Bio, TNFi, and IL-6Ri periods, respectively. In adjusted models, both TNFi and IL-6Ri were associated with lower relapse rates than the No Bio period (TNFi: IRR 0.4, 95% CI 0.2-0.8; adjusted rate difference, -54.0 events per 100 person-years, 95% CI -141.5 to -5.5; IL-6Ri: IRR 0.2, 95% CI 0.1-0.4; adjusted rate difference, -68.3 events per 100 person-years, 95% CI -149.8 to -21.4). Hospitalised infection estimates were imprecise (TNFi: IRR 0.3, 95% CI 0.1-1.4; IL-6Ri: IRR 0.7, 95% CI 0.2-2.6). CONCLUSION: Biologic exposure was associated with lower relapse rates than during No Bio periods in RP, whereas estimates for hospitalised infection were imprecise.
Reference Key
openalex_W7164556469 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yoichi Nakayama, Yuki Aitani, Mirei Shirakashi, Toshiki Nakajima, Tsuneyasu Yoshida, Nozomi Nishimura, Tsuneo Sasai, Ryosuke Hiwa, Hideaki Tsuji, Shuji Akizuki, Kosaku Murakami, Ran Nakashima, Akio Morinobu, Hajime Yoshifuji
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag305
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.